← Back to all trials
Completed
NCT05713773
Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects
Conditions: Metabolic Syndrome, Obesity
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 20
Sponsor: Aphaia Pharma US LLC
Location: Romania
Summary
This single-dose, randomized, open label, five-treatment, five-period, five-sequence crossover study was performed to assess pharmacodynamics (PD) and pharmacokinetics (PK) of three new developed coated Glucose beads formulations (containing glucose (8 g) and caffeine), one coated Glucose beads formulation (containing glucose (8 g)) and one uncoated Glucose beads formulation (containing Glucose (8 g) and caffeine) after single-dose administration (fasting conditions) in 20 obese healthy subjects.
After an overnight fasting of at least 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
At least 3 days wash-out period was kept between each treatment periods.
Eligibility Criteria
Inclusion Criteria:Healthy obese, Caucasian male and female subjects 18 - 55 years of ageBody mass index within the range of > 30.0 kg/m2Waist circumference: men > 102 cm; women > 88 cmFemale subjects of childbearing potential agree to undergo pregnancy tests and to use an appropriate method of contraception (i.e., oral contraceptive steroids, intrauterine device, barrier method)Findings within the range of clinical acceptability in medical history (or the clinical investigator considers the deviation to be irrelevant for the purpose of the study)Findings within the range of clinical acceptability in physical examination (or the clinical investigator considers the deviation to be irrelevant for the purpose of the study)Laboratory values within the normal range (or the clinical investigator considers the deviation to be irrelevant for the purpose of the study)Normal ECG or abnormalities which the clinical investigator does not consider a disqualification for participation in the studyNormal vital signs (normal blood pressure and heart rate measured under stabilized conditions at screening visit after at least 5 minutes of rest in sitting position) or abnormalities which the clinical investigator does not consider a disqualification for participation in the studyNormal gastrointestinal (GI) function or abnormalities which the clinical investigator does not consider a disqualification for participation in the studyWillingness to undergo screening and follow-up examinations (i.e., physical examinations and laboratory investigations before and after the treatment periods)Ability to comprehend subject information and willingness to sign the informed consentNon-smokers or mild to moderate smokers (less or equal 10 cigarettes daily)Exclusion Criteria:Gastrointestinal, hepatic and renal diseases and/or pathological findings which might interfere with pharmacokinetics and pharmacodynamics of the investigational productEstablished diagnosis of type-1 or type-2 diabetes mellitusTreatment with insulin, insulin secretagogues (sulfonylurea derivatives, glinides, GLP-1 agonists (exenatide, lixisenatide, glutides), or thiazolidinediones (glitazones)Unexplained rise in blood glucoseTreatment for constipation (including but not limited to lactulose or any other form of stool softeners, laxatives) or diarrhea (including but not limited to pectins.
loperamide etc.) or any other medication known to interfere with gastrointestinal transit time, such as e.g., metoclopramide, opioids, or gastric Potential of Hydrogen (pH) (including but not limited to antacids, H2-receptor antagonists, prazole)Tea, coffee or other caffeine containing beverage drinkers (more than 0.4 L per day)History of hypersensitivity to the investigational product or any related drugs or to any of the excipientsHistory or presence of any clinically significant cardiovascular, pulmonary, hepatobiliary, renal, hematological, gastrointestinal, endocrinologic, immunologic, dermatologic.
neurological, psychiatric, metabolic, musculoskeletal, or malignant disease, which the clinical investigator does not consider a disqualification for participation in the studyKnown heart failure (Grade I to IV of New York Heart Association classification)Significant renal disease.
including nephritic syndrome chronic renal failure (defined as creatinine clearance< 60 mL/min and serum creatinine >180 μmol/L)Unexplained serum creatine phosphokinase (CPK) > 3-times the upper limit of normal (ULN) Subjects with a reason for CPK elevation may have the measurement repeated prior to randomization a CPK retest> 3-times ULN leads to exclusionClinically significant illness or surgery within 4 weeks prior to dosingLess than 14 days after last acute diseaseVolunteers liable to orthostatic dysregulation, fainting, or blackoutsDonation or loss of blood equal to or exceeding 500 ml during 90 days before the first administration of investigational productParticipation in another study with an experimental drug within at least 3 months (or within five elimination half-lives of the previous experimental drug, whichever is longer) before the first administration of investigational productAny use of drug, prescribed or over-the-counter (OTC) (inclusive herbal remedies), within 2 weeks (or within six elimination half-lives of this medication, whichever is longer) prior to the first administration of investigational product except if this will not affect the outcome of the study in the opinion of the clinical investigatorUnwillingness or inability to comply with the study protocol or study-related procedures (e.g., difficulty to stay fasting, consume the standard meals, or swallow the beads formulations; difficult venous access).
Source: ClinicalTrials.gov (NCT05713773). StuddyBuddy aggregates publicly available trial information.
